Epidermal growth factor receptor controls glycogen phosphorylase in T cells through small GTPases of the RAS family.

GTPase RAS protein Raf kinase adaptive immunity adenylate cyclase (adenylyl cyclase) cAMP-regulated guanine nucleotide exchange factor II (EPAC2) cell signaling. epidermal growth factor receptor (EGFR) glycogen phosphorylase phosphorylase

Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
22 03 2019
Historique:
received: 23 10 2018
revised: 07 01 2019
pubmed: 17 1 2019
medline: 18 12 2019
entrez: 17 1 2019
Statut: ppublish

Résumé

We recently uncovered a regulatory pathway of the muscle isoform of glycogen phosphorylase (PYGM) that plays an important role in regulating immune function in T cells. Here, using various enzymatic, pulldown, and immunoprecipitation assays, we describe signaling cross-talk between the small GTPases RAS and RAP1A, member of RAS oncogene family (RAP1) in human Kit 225 lymphoid cells, which, in turn, is regulated by the epidermal growth factor receptor (EGFR). We found that this communication bridge is essential for glycogen phosphorylase (PYG) activation through the canonical pathway because this enzyme is inactive in the absence of adenylyl cyclase type 6 (ADCY6). PYG activation required stimulation of both exchange protein directly activated by cAMP 2 (EPAC2) and RAP1 via RAS and ADCY6 phosphorylation, with the latter being mediated by Raf-1 proto-oncogene, Ser/Thr kinase (RAF1). Consistent with this model, PYG activation was EGFR-dependent and may be initiated by the constitutively active form of RAS. Consequently, PYG activation in Kit 225 T cells could be blocked with specific inhibitors of RAS, EPAC, RAP1, RAF1, ADCY6, and cAMP-dependent protein kinase. Our results establish a new paradigm for the mechanism of PYG activation, which depends on the type of receptor involved.

Identifiants

pubmed: 30647127
pii: S0021-9258(20)39009-8
doi: 10.1074/jbc.RA118.005997
pmc: PMC6433075
doi:

Substances chimiques

Guanine Nucleotide Exchange Factors 0
MAS1 protein, human 0
Proto-Oncogene Mas 0
RAPGEF4 protein, human 0
Glycogen Phosphorylase EC 2.4.1.-
ErbB Receptors EC 2.7.10.1
GTP Phosphohydrolases EC 3.6.1.-
rap1 GTP-Binding Proteins EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4345-4358

Informations de copyright

© 2019 Llavero et al.

Déclaration de conflit d'intérêts

The authors declare that they have no conflicts of interest with the contents of this article.

Références

Mol Cancer Ther. 2007 Jun;6(6):1765-73
pubmed: 17541036
Neuromuscul Disord. 2014 Dec;24(12):1079-86
pubmed: 25240406
Mol Pharmacol. 2005 Jan;67(1):250-9
pubmed: 15470083
Nat Cell Biol. 2002 Nov;4(11):901-6
pubmed: 12402047
Nat Cell Biol. 2003 Jul;5(7):633-9
pubmed: 12819788
FEBS Lett. 2007 Dec 22;581(30):5814-8
pubmed: 18047838
Semin Cancer Biol. 2019 Feb;54:14-28
pubmed: 29175106
Immunity. 2017 Oct 17;47(4):710-722.e6
pubmed: 29045902
Cell Signal. 2016 Nov;28(11):1713-24
pubmed: 27519475
Cancer Treat Rev. 2017 Feb;53:61-69
pubmed: 28073102
Biochim Biophys Acta. 1970 Aug 15;212(2):257-68
pubmed: 4318155
Korean J Physiol Pharmacol. 2017 Jul;21(4):397-405
pubmed: 28706453
Dev Cell. 2005 Mar;8(3):303-4
pubmed: 15737926
Curr Top Cell Regul. 1981;18:401-19
pubmed: 6268366
Arch Ophthalmol. 2001 Mar;119(3):373-7
pubmed: 11231770
Biochim Biophys Acta. 1986 Jan 15;880(1):78-90
pubmed: 3510670
EMBO J. 2003 Jul 1;22(13):3326-36
pubmed: 12839994
J Biol Chem. 2008 Dec 26;283(52):36454-64
pubmed: 18974050
J Biol Chem. 1997 Oct 24;272(43):27224-9
pubmed: 9341167
J Biol Chem. 2012 Apr 6;287(15):11878-90
pubmed: 22337875
Exp Cell Res. 2005 Sep 10;309(1):161-73
pubmed: 15963501
J Thorac Oncol. 2011 Aug;6(8):1435-7
pubmed: 21847063
Sci Rep. 2015 Mar 20;5:9344
pubmed: 25791905
J Biol Chem. 1978 Dec 25;253(24):9097-101
pubmed: 721833
Cell. 2000 Oct 13;103(2):227-38
pubmed: 11057896
Cell. 2000 Oct 13;103(2):211-25
pubmed: 11057895
Mol Cell Biol. 2008 Dec;28(23):7109-25
pubmed: 18824540
J Immunol. 1988 Jan 1;140(1):208-14
pubmed: 2447168
J Biol Chem. 2013 Jun 21;288(25):18407-20
pubmed: 23645677
Nat Rev Mol Cell Biol. 2011 Feb;12(2):104-17
pubmed: 21252999
J Biol Chem. 2015 Apr 3;290(14):9171-82
pubmed: 25694429
FEBS Lett. 1975 Mar 1;51(1):29-32
pubmed: 164381
Cancer Res. 1997 May 15;57(10):1846-50
pubmed: 9157972
Immunity. 2013 Feb 21;38(2):275-84
pubmed: 23333074
Oncogene. 2000 Mar 16;19(12):1596-604
pubmed: 10734320
Nutr Healthy Aging. 2017 Dec 7;4(3):195-205
pubmed: 29276789
J Biol Chem. 1986 Mar 5;261(7):3043-7
pubmed: 3005278
Eur J Cancer. 2001 Sep;37 Suppl 4:S3-8
pubmed: 11597398
Biochim Biophys Acta. 2002 Feb 15;1570(1):53-62
pubmed: 11960689
J Cell Sci. 2005 Mar 1;118(Pt 5):843-6
pubmed: 15731001
Blood. 2005 Nov 1;106(9):2952-61
pubmed: 16076873
Nat Cell Biol. 2014 Oct;16(10):972-7
pubmed: 25173978
Blood. 1987 Oct;70(4):1069-72
pubmed: 3115332
Cell. 2017 Jun 29;170(1):17-33
pubmed: 28666118
Biochem J. 2002 Oct 15;367(Pt 2):443-50
pubmed: 12099891
Oncogene. 2005 May 12;24(21):3512-24
pubmed: 15735670
Trends Cell Biol. 2002 Jun;12(6):258-66
pubmed: 12074885
J Autoimmun. 2008 Aug;31(1):7-12
pubmed: 18442895
Cell Death Dis. 2012 Dec 20;3:e445
pubmed: 23254288
Nat Cell Biol. 2002 Aug;4(8):621-5
pubmed: 12134164
Nature. 1998 Dec 3;396(6710):474-7
pubmed: 9853756
Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22369-74
pubmed: 20018733
Glia. 2015 Jan;63(1):154-62
pubmed: 25130497
Curr Biol. 2005 Jul 26;15(14):R563-74
pubmed: 16051167
J Biol Chem. 1968 Sep 10;243(17):4641-9
pubmed: 5684013
Tetrahedron Lett. 2013 Mar 20;54(12):1546-1549
pubmed: 23459418
Oncogene. 2004 Jul 29;23(34):5823-33
pubmed: 15184873
J Med Chem. 2009 Jan 8;52(1):197-205
pubmed: 19072665

Auteurs

Francisco Llavero (F)

From the Achucarro Basque Center for Neuroscience, Science Park of the Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), 48940 Leioa, Spain, francisco.llavero@ehu.eus.

Miriam Luque Montoro (M)

From the Achucarro Basque Center for Neuroscience, Science Park of the Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), 48940 Leioa, Spain.

Alazne Arrazola Sastre (A)

From the Achucarro Basque Center for Neuroscience, Science Park of the Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), 48940 Leioa, Spain.
the Department of Genetics, Physical Anthropology, and Animal Physiology, Faculty of Science and Technology, UPV/EHU, 48940 Leioa, Spain.

David Fernández-Moreno (D)

the Research Institute of the Hospital 12 de Octubre ("i+12"), 28041 Madrid, Spain.
the Faculty of Sports Science, Universidad Europea de Madrid, 28670 Madrid, Spain.

Hadriano M Lacerda (HM)

Three R Labs, Science Park of the UPV/EHU, 48940 Leioa, Spain.

Luis A Parada (LA)

the Instituto de Patología Experimental, Universidad Nacional de Salta, A4400 Salta, Argentina, and.

Alejandro Lucia (A)

the Research Institute of the Hospital 12 de Octubre ("i+12"), 28041 Madrid, Spain.
the Faculty of Sports Science, Universidad Europea de Madrid, 28670 Madrid, Spain.

José L Zugaza (JL)

From the Achucarro Basque Center for Neuroscience, Science Park of the Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), 48940 Leioa, Spain, joseluis.zugaza@ehu.es.
the Department of Genetics, Physical Anthropology, and Animal Physiology, Faculty of Science and Technology, UPV/EHU, 48940 Leioa, Spain.
IKERBASQUE, Basque Foundation for Science, 48013 Bilbao, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH